|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that the Board of Directors has granted 500,000 options at an exercise price of $0.15 per share to Mr. Christopher Moreau, President and CEO, in accordance with the Company’s stock option plan. The options are subject to regulatory approval
Read More
|
|
Internal Review Confirms Set of Compelling Markers Including a Single Marker With 72% Sensitivity at 95% Specificity Miraculins Inc. a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that it has completed the internal review of its gastric cancer program and has confirmed seven blood based protein biomarkers of interest for their potential to separate gastric cancer patients from non-gastric cancer patients. This includes a single marker that performs with a 72% sensitivity at 95% specificity (AUC=0.925) known as MIR-GP1. Based on this promising result, the Company plans to advance this program by identifying these markers through protein purification and amino acid sequencing, beginning with MIR-GP1.
Read More
|
|
Company develops functioning prototype assay for detecting PSP94 in urine Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that the Company has completed development of a prototype assay for PSP94 (Prostate Secretory Protein) on the Luminex Bio-Plex 200 Protein Array System and plans to manufacture and begin selling PSP94 based test kits for research purposes by the end of 2008. As previously disclosed by Miraculins, PSP94 plays a significant role in the Company’s P2V™ panel test that is currently being internally developed.
Read More
|
|
Preeclampsia is the Leading Cause of Maternal and Prenatal Deaths Worldwide
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a term sheet with Mount Sinai Hospital to acquire a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide.
Read More
|
|
Miraculins Inc., today announces a strategic shift in priorities that will move the Company’s focus further down the diagnostic assay development and commercialization pathway. The Company’s business plan will focus on in-licensing/acquiring and developing both cancer and non-cancer diagnostic opportunities that have completed early stage research and address unmet clinical needs. Although the Company will move away from basic proteomic research and discovery it continues the assay development of its internally discovered P2V™ prostate cancer diagnostic test with a major pivotal validation study underway that is expected to be completed by the end of 2008.
Read More
|
|
|